Aravive Biologics, Inc., is an innovative pharmaceutical company dedicated to translating fundamental biological insights into new therapies that address major unmet clinical needs. Our approach is to target critical survival pathways both for hematologic malignancies as well as advanced solid tumors.
Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and Albert Koong at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, use our high-affinity decoy receptors, outcompete cancer’s ability to grow, metastasize and acquire resistance to treatments.
We expect our unique cancer therapies will offer more effective results either as a monotherapy or in combination with other cancer therapies, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.
Aravive-S6, our lead product candidate, is a novel, high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. We have generated strong preclinical data for Aravive-S6 in both acute myeloid leukemia and certain advanced solid tumors including ovarian, pancreatic, and breast cancers. Our current development programs benefit from the availability of complementary diagnostics that we expect will accelerate drug development and reduce risk by allowing better selection of responder patient populations. This should enable more focused clinical trials and increase the likelihood of success by providing clinical biomarkers for tracking patient response.
Aravive is based in Houston, Texas, where it relocated after receiving a $20 million Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.